GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Grace Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.88−0.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Grace Therapeutics from other investors
No posts about GRCE yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.